OBJECTIVE: To determine the efficacy of selective and superselective neck dissection for patients with bulky or residual nodal metastasis treated with concomitant intra-arterial cisplatin and radiotherapy. DESIGN: Prospective study. SETTING: University of Tennessee, Memphis. PATIENTS: A total of 240 patients with stage III or IV head and neck squamous cell carcinoma. INTERVENTIONS: Treatment with cisplatin, 150 mg/m2 intra-arterially, and sodium thiosulfate, 9 g/m2 intravenously, weekly for 4 weeks; and radiotherapy, 2 Gy per fraction per day, 5 times weekly, for a total of 68 to 74 Gy over 6 to 7 weeks. MAIN OUTCOME MEASURES: Regional control, distant metastases, and overall survival for patients undergoing radical or modified radical neck dissection (n = 12), selective neck dissection (n = 65), and superselective neck dissection (levels II-III only) (n = 7). RESULTS: Among the total group of 240 patients, 106 neck dissections were performed on 84 patients who had bulky nodal disease. With a median follow-up of 58 months (range, 12-96 months), regional failure occurred in 11 (4.6%) of 240 patients: 2 (17%) of the 12 who had modified radical neck dissection, 3 (5%) of the 65 who had selective neck dissection, none of the 7 patients who had superselective neck dissection, and 6 (4%) of the 156 who had no neck dissection. The rates of overall survival and distant metastases were not significantly different among the 3 neck dissection subsets. CONCLUSION: Selective and superselective neck dissection, which spare function and minimize morbidity, are viable therapeutic alternatives for patients with residual disease confined to 1 level after intra-arterial chemoradiation treatment, and possibly for other chemoradiation protocols.
OBJECTIVE: To determine the efficacy of selective and superselective neck dissection for patients with bulky or residual nodal metastasis treated with concomitant intra-arterial cisplatin and radiotherapy. DESIGN: Prospective study. SETTING: University of Tennessee, Memphis. PATIENTS: A total of 240 patients with stage III or IV head and neck squamous cell carcinoma. INTERVENTIONS: Treatment with cisplatin, 150 mg/m2 intra-arterially, and sodium thiosulfate, 9 g/m2 intravenously, weekly for 4 weeks; and radiotherapy, 2 Gy per fraction per day, 5 times weekly, for a total of 68 to 74 Gy over 6 to 7 weeks. MAIN OUTCOME MEASURES: Regional control, distant metastases, and overall survival for patients undergoing radical or modified radical neck dissection (n = 12), selective neck dissection (n = 65), and superselective neck dissection (levels II-III only) (n = 7). RESULTS: Among the total group of 240 patients, 106 neck dissections were performed on 84 patients who had bulky nodal disease. With a median follow-up of 58 months (range, 12-96 months), regional failure occurred in 11 (4.6%) of 240 patients: 2 (17%) of the 12 who had modified radical neck dissection, 3 (5%) of the 65 who had selective neck dissection, none of the 7 patients who had superselective neck dissection, and 6 (4%) of the 156 who had no neck dissection. The rates of overall survival and distant metastases were not significantly different among the 3 neck dissection subsets. CONCLUSION: Selective and superselective neck dissection, which spare function and minimize morbidity, are viable therapeutic alternatives for patients with residual disease confined to 1 level after intra-arterial chemoradiation treatment, and possibly for other chemoradiation protocols.
Authors: Juliette Thariat; K Kian Ang; Pamela K Allen; Anesa Ahamad; Michelle D Williams; Jeffrey N Myers; Adel K El-Naggar; Lawrence E Ginsberg; David I Rosenthal; Bonnie S Glisson; William H Morrison; Randal S Weber; Adam S Garden Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-01 Impact factor: 7.038
Authors: Marc Hamoir; Carl E Silver; Sandra Schmitz; Robert P Takes; Alessandra Rinaldo; Juan P Rodrigo; K Thomas Robbins; Karen T Pitman; Jesus E Medina; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2012-10-30 Impact factor: 2.503
Authors: Carlos Suárez; Juan P Rodrigo; K Thomas Robbins; Vinidh Paleri; Carl E Silver; Alessandra Rinaldo; Jesus E Medina; Marc Hamoir; Alvaro Sanabria; Vanni Mondin; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-01-16 Impact factor: 2.503
Authors: K Thomas Robbins; Alfio Ferlito; Jatin P Shah; Marc Hamoir; Robert P Takes; Primož Strojan; Avi Khafif; Carl E Silver; Alessandra Rinaldo; Jesus E Medina Journal: Eur Arch Otorhinolaryngol Date: 2012-08-19 Impact factor: 2.503
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: H Hakan Coskun; Jesus E Medina; K Thomas Robbins; Carl E Silver; Primož Strojan; Afshin Teymoortash; Phillip K Pellitteri; Juan P Rodrigo; Sandro J Stoeckli; Ashok R Shaha; Carlos Suárez; Dana M Hartl; Remco de Bree; Robert P Takes; Marc Hamoir; Karen T Pitman; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2014-06-30 Impact factor: 3.147
Authors: Giulia Bertino; Antonio Occhini; Carlo Emilio Falco; Camillo Porta; Franco Corbella; Sara Colombo; Vittoria Balcet; Patrizia Morbini; Federico Zappoli; Andrea Azzaretti; Giuseppe Rodolico; Carmine Tinelli; Marco Benazzo Journal: BMC Cancer Date: 2009-09-04 Impact factor: 4.430